Who Are the Core Customers in DexCom Company's Target Market?

DexCom target market centers on people with diabetes who require intensive insulin therapy – nearly all Type 1 diabetes patients and Type 2 diabetes patients on intensive insulin – where DexCom customers deliver the bulk of recurring sensor sales and revenue; Type 1 diabetes patients using Dexcom drive high sensor utilization and retention.

DexCom pursues the >25 million non-insulin-using Type 2 population in the U.S. with Stelo (first CGM cleared for non-insulin users) and targets endocrinologists and diabetes specialists plus primary care physicians who recommend CGM; diabetes educators and caregivers also influence uptake.

DexCom serves a mixed base: direct-to-consumer chronic disease users and institutional buyers (providers, payers). Remote patient monitoring for diabetes with DexCom and Medicare coverage programs shape reimbursement-driven uptake.

The insulin-intensive cohort remains most important by revenue and usage intensity – continuous glucose monitoring users on insulin generate recurring sensor and transmitter sales; the non-insulin Type 2 segment offers the largest addressable market for long-term growth.

The US remains the primary revenue engine for Dexcom target market activity, accounting for roughly ~70% of 2025 revenue per company disclosures, supported by CMS coverage expansion for basal-only insulin users that added millions of eligible beneficiaries and boosted Dexcom customers in Medicare cohorts.

Europe and Japan show accelerated uptake as Dexcom, Inc. secures broader reimbursement and scales manufacturing; combined international revenue grew to about ~30% of total in 2025 with especially fast adoption among endocrinologists and diabetes specialists.

Demand has shifted toward the retail pharmacy channel versus traditional DME, lowering barriers for continuous glucose monitoring users; Dexcom's 2025 entry into OTC opened a consumer wellness and pre-diabetes channel, increasing access through pharmacies and employers offering devices via benefits.

Highest growth is among Type 2 diabetes patients on insulin and people seeking real time glucose monitoring devices, plus pediatric Type 1 diabetes patients and caregivers; remote patient monitoring integrations and hospital diabetes management programs are also expanding uptake.

DexCom adds new customers by launching G7 globally and rolling out Stelo, targeting continuous glucose monitoring users beyond Type 1 into Type 2 on insulin and non – insulin users, and by enabling Direct – to – Watch and metabolic health features that appeal to caregivers and primary care physicians.

High retention comes from frequent sensor recurrences (recurring revenue), superior clinical outcomes shown in peer data, tight integration with insulin pumps and remote patient monitoring, and high switching costs as endocrinologists and diabetes specialists standardize on Dexcom systems.

Repeat demand stems from subscription – style sensor purchases; in 2025 sensor volumes scaled with a growing base, driving recurring revenue. Care programs for pediatric Type 1 diabetes patients, Medicare coverage pathways, and partnerships with pharmacies reinforce renewals and clinician recommendations.

The key lever is platformization: converting DexCom, Inc. from a device maker to a metabolic health platform – G7 global rollout plus Stelo market penetration – boosts lifetime value via data – driven outcomes and expands Dexcom core customers to include adults with Type 2, pregnant women with gestational diabetes, and employers offering CGM benefits. Read more on operations and revenue mechanics How DexCom Company Works and Makes Money.